

CHUGAI PHARMACEUTICAL CO., LTD.  
Corporate Communications Dept.

1-1, Nihonbashi-Muromachi 2-chome,  
Chuo-ku Tokyo, 103-8324 Japan  
TEL: +81-(0)3-3273-0881  
FAX: +81-(0)3-3281-6607  
E-mail: pr@chugai-pharm.co.jp  
URL: <http://www.chugai-pharm.co.jp>



## Translation

### Supply Plan of "Tamiflu<sup>®</sup>" Anti-influenza Drug for the 2013-2014 Season

October 24, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. (hereafter, "Chugai") [Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] announced today that a supply plan of the anti-influenza drug "Tamiflu<sup>®</sup> Capsule 75" and "Tamiflu<sup>®</sup> Dry Syrup 3%" (generic name: oseltamivir phosphate) (hereafter, Tamiflu<sup>®</sup>) imported from F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] for the 2013-2014 season (hereafter, this season) for Japan has been prepared.

Supply plan for this season (as of October 24, 2013)

|  |                               |
|--|-------------------------------|
| Tamiflu <sup>®</sup> Capsule 75        | 5.0 million treatment courses |
| Tamiflu <sup>®</sup> Dry Syrup 3%      | 3.0 million treatment courses |
| Total of 8.0 million treatment courses |                               |

Chugai will consider supplying further if the size of the epidemic of influenza expands.

Chugai is determined to be ready for the supply of Tamiflu<sup>®</sup> in preparation for the epidemic of influenza.

Tamiflu<sup>®</sup> is trademark of F. Hoffmann-La Roche Ltd., Basel, Switzerland.